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loppement. De plus,  les multinationales pharmaceutiques ont utilisé 
la situation des pays pauvres pour en tirer profit. Ainsi, elles mènent 
des essais cliniques selon des directives éthiques moins strictes que 
celles exigées en Occident ; puis elles commercialisent des médica-
ments potentiellement dangereux et nocifs. En plus, les recherches in-
dispensables sur les maladies tropicales sont négligeables. Les voix des 
activistes ont été plus fortes que jamais, mais ont-elles assez d’effet ? 
Serait-il possible d’inciter cette industrie de plusieurs milliards à mener 
des actions en faveur de l’équité et des droits de l’homme, au lieu d’être 
singulièrement portée sur les bénéfices ?
Key Words / Palabras clave / Mots-clé 
Big Pharma Policies, Developing Countries, Human Rights.
Políticas de las grandes farmacéuticas, países en desarrollo, derechos 
humanos.
Politiques des grandes pharmaceutiques, pays en développement, 
Droits de l’Homme.
22 January, 2014: Marijn Dekkers, Dutchman and CEO of 
Bayer (‘Science for a Better Life’), made a statement in a 
public forum that went viral over the internet and caused 
outrage among activists. Bayer marketed a new cancer 
drug called Nexavar in India for over 4000 euro/month 
while the Indian generic industry was able to produce an 
equivalent for 99 euro/month, making it accessible for pa-
tients in need. But Bayer started a court case to prevent 
this. Mr. Dekkers said: We did not develop a cancer medi-
cine for Indians. We developed it for Western patients who 
can afford it’. 
Abstract / Resumen / Résumé 
About a third of the world’s population does not have regular access 
to essential medicines today. This is partly caused by Big Pharma’s 
policies to maintain high drug prices and hold on to exclusive rights 
for their production, causing them to be completely out of reach for 
developing countries. But apart from this, there are other ways in which 
multinational pharmaceutical companies have taken advantage of the 
situation in poor countries. Clinical trials are conducted according to 
less strict ethical guidelines than in the West, and old drugs that are 
potentially dangerous and harmful are actively marketed in the devel-
oping world. Much-needed research efforts into tropical diseases are 
negligible. Activist voices have been stronger than ever before-but do 
they have enough effect? Can this multi-billion industry be incentiv-
ized to spearhead equity and human rights instead of being singularly 
focused on profit?
En la actualidad, alrededor de un tercio de la población no tiene acceso 
a los medicamentos esenciales. Esto se debe en parte a las políticas de 
las grandes farmacéuticas consistentes en mantener unos precios altos 
y unos derechos de exclusividad de su producción, lo que provoca que 
ésta quede completamente fuera del alcance de los países en vías de 
desarrollo. Además, las multinacionales farmacéuticas se han aprove-
chado de los problemas de los países pobres de manera que se llevan a 
cabo pruebas clínicas con menos controles éticos que en Occidente y se 
comercializan medicamentos antiguos potencialmente peligrosos y per-
judiciales. Por otra parte, no se acomete la necesidad de investigar en 
enfermedades tropicales. Pese a que la voz de los activistas es cada vez 
más poderosa, ¿ha causado algún efecto? ¿Se puede incentivar de algún 
modo a esta industria que mueve miles de millones para que se ponga 
al frente de la igualdad y los derechos humanos en lugar de orientarse 
exclusivamente a la generación de beneficios económicos?
Aujourd’hui, environ un tiers de la population mondiale n’a pas d’accès 
aux médicaments essentiels. Ceci est dû, en partie, aux politiques sui-
vies par les grandes sociétés pharmaceutiques pour maintenir les prix 
élevés des médicaments et détenir les droits exclusifs de production, 
ce qui les rend tout à fait hors de portée pour les pays en voie de déve-
?
?
?
?
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(Figure 1, Big Pharma Charges Unaffordable Prices for 
Medicines in India, infographic MSF)
The response of Manica Balasegaram of Médecins Sans 
Frontières (MSF’s) Access to Medicines Campaign is that 
‘this statement sums up everything that is wrong with the 
multinational pharmaceutical industry today; drug compa-
nies, claiming to care about Global Health, do not act ac-
cordingly and are part of the problem instead of part of the 
solution’.1 Instead, the pharmaceutical industry is profit-
driven and very successful at that. The combined worth of 
the world’s top five drug companies is twice the combined 
GDP of sub-Saharan Africa and according to IMS Health 
the global pharmaceutical industry is expected to rise to 
the worth of US$1.1 trillion by 2014. 
But from being widely admired for its integrity, noble ide-
als and altruism, the pharmaceutical industries reputation 
has sunk to being ‘distrusted and devalued’, with a ‘broken 
image’.2 According to a survey in 2012 in 56 countries the 
pharmaceutical industries reputation is at an all time low.3 
The main reason people gave for their poor rating was the 
industries failure to help patients in low –and middle in-
come countries to gain access to medicines– the general 
opinion held was that “profit comes before making people 
well”. 
Contrary to this survey, Hans Hogerzeil, former director of 
WHO’s Essential Medicines and Pharmaceutical Policies 
department, stated in September last year that the phar-
maceutical industry as a whole is making progress, and 
is becoming more organized in its approach to global ac-
cess to medicines.4 This was based on the 2012 ‘Access to 
Medicine Index’, in which the 20 largest pharmaceutical 
companies were assessed for their efforts in making drugs 
accessible to the world’s poorest.
However Ellen ‘t Hoen, the world’s foremost activist on 
the issue of global drug patents and human rights states 
that this progress has only been made due to 10 years of 
continued activism, with no or little impetus coming from 
the industry itself.5 
Activism was kick-started and the term ‘access to drugs’ 
was coined in early 1998, when 41 drug companies sued 
South Africa, the country that had experienced an explo-
sive spread of HIV/AIDS and until today has the highest 
number of cases worldwide. The legal fight was over a new 
law, under Nelson Mandela’s regime, that would make low-
cost copies of expensive Western anti-retroviral drugs avail-
able to patients. These drugs would prevent a certain death 
from AIDS, but were far too expensive for South African 
patients with a price tag of US$10,000 to 15,000 per patient 
per year. The new law would radically change this situation 
and save millions of lives, but the opposition of Big Pharma 
was relentless. Only in April 2001, after a global outcry, the 
lawsuit was dropped. This was the start of the reversal of the 
HIV/AIDS epidemic in Africa - now, due to continued ac-
tivism, antiretrovirals have become accessible for over five 
million people in the developing world.5 
1 Manica Balasegaram: Drugs for the poor, drugs for the rich—why 
the current research and development model doesn’t deliver. Feb 13, 
2014, British Medical Journal blog
2 Devalued and Distrusted: Can the Pharmaceutical Industry Restore 
its Broken Image?
 John L. LaMattina, Feb 2013, ISBN: 978-1-118-48747-1
3 Corporate reputation of Pharma – the patient perspective. Feb 2014, 
Patient View Report. 
4 Hans V Hogerzeil, Jayasree K Iyer, Lisanne Urlings, Tara Prasad 
and Sara Brewer. Is the pharmaceutical industry improving with re-
gard to access to essential medicines? The Lancet Global Health 2, 
3, 139-140 (March 2014)
5 E’t Hoen, J Berger, A Calmy. Driving a decade of change: HIV/
AIDS, patents and access to medicines for all. J Int AIDS Soc 14, 
15, 2011
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But today, history is repeating itself. The 17th of January 
this year, leaked documents revealed that Big Pharma had 
allocated 600,000 USD for a large-scale public relations 
campaign against South Africa’s new plan to decrease drug 
prices in the country.6 The plan would modify the countries 
patent system in order to serve public health, and ensure 
that monopolies on drugs could no longer be extended by 
changing a formulation or combining two medicines into 
a single tablet, and then patenting this change. This prac-
tice of patent ‘evergreening’ is a long-known strategy of 
the industry in Europe and the US. It keeps drug prices 
artificially high as it postpones generic competition. The 
hidden agenda of Big Pharma was painfully exposed; they 
will go far to prevent South Africa from taking the lead 
once more. Africa is an emerging economy, with its rap-
idly growing cities offering a considerable future market 
for pricey drugs. Pharmaceutical spending in Africa may 
reach $30 billion by 2016, from approximately $18 billion 
at present. Big Pharma’s strategy is based on keeping high 
prices firmly in place through holding on to intellectual 
property rights and patents in these emerging markets, to 
the disadvantage of the world’s poor.
A similar legal fight on ‘evergreening’ took place half a 
year earlier in India. Novartis (‘Caring and Curing’) lost a 
six-year long battle after the Indian court ruled that small 
changes and improvements to a new cancer drug, called 
Glivec, were not enough reason to prolong its patent in In-
dia. This allowed Indian firms to immediately market cheap 
generic copies (Glivec costs over 2000 USD/month). In 
an interview before the ruling, Novartis threatened to stop 
supplying India with any new medicines if it did not get 
patent protection. “If the situation stays as it is now, all im-
provements on an original compound are not protectable 
and such drugs would probably not be rolled out in India”, 
Paul Herrling, who headed the company’s legal battle in 
India, told the Financial Times.7 “Why would we?”
Apart from the legal battles and the cajoling of govern-
ments of resource-poor countries, Big Pharma arguments 
that the exceedingly high prices of new drugs are justified 
because of their research and development (R&D) costs; 
lowering drug prices would endanger global medical in-
novation. Recently, a staggering price of 5 billion US$ per 
drug was calculated based on quotes of drug companies.8 
But there is a great lack of transparency in these quotes, 
and they are often questioned, even by the industry itself; 
last year, GSK’s Andrew Witty called a previously quoted 
$1 billion figure “one of the great myths of the industry”.9 
MSF’s Access to Medicines Campaign claims that global-
ly, about half of R&D is not even financed by the industry, 
but subsidized by governments and philanthropic organi-
zations.1 The public-private partnership DNDi (Drugs for 
Neglected Diseases initiative) demonstrated that innova-
tive drugs could be developed for 100-150 million US$ – a 
fraction of the numbers used by the industry.10 
In the 2012 Access to Medicine Index, the lowest scores 
were obtained for progress related to patents and data ex-
clusivity. 
(Figure 2, Changes in six core ATM indicators, 2010–12)4
Global access to drugs was most successfully increased by 
large scale drug donations. These have been the answer of 
Big Pharma to the world’s heavy criticism. Drug d onation 
6 MSF urges South Africa to stand strong in defiance of aggressive 
pharma moves to delay change. Jan 20, 2014, MSF Access Cam-
paign 
7 Novartis warns India over drug patent. Andrew Jack and Amy Ka-
zmin. Mar 31, 2013, Financial Times
8 The cost of creating a new drug now $5 billion, pushing Big Pharma 
to change. Matthew Herper, Pharma and Health Care, www.forbes.
com. Nov 8, 2013. 
9 GlaxoSmithKline boss says new drugs can be cheaper. Ben Hirschler. 
Mar 14, 2013, www.reuters.com
10 Research & Development for Diseases of the Poor: A 10-Year 
Analysis of Impact of the DNDi Model. Press release DNDi, Dec 5, 
2013. www.dndi.com
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programs are tax deductible, don’t have implications for 
drug pricing in general, and are now almost routinely un-
dertaken as part of company strategy. Examples are “Mer-
ck’s Gift,” the program where billions of river blindness 
drugs were donated for Africa, Pfizer’s donation of free or 
discounted fluconazole and other drugs for HIV in South 
Africa and GSK’s commitment to donate albendazole tab-
lets for the elimination of lymphatic filariasis worldwide. 
These initiatives have helped to create highly successful 
control programs, but laudable as they are, there are draw 
backs - diseases for which the industry provides cures now 
dominate the public health agenda, whilst other, more diffi-
cult to tackle problems, such as diarrhea or maternal death 
during childbirth do not get the attention they deserve. 
Apart from its Patents-Before-People policy, how are Big 
Pharma operating in poor countries? 
Ben Goldacre is a British doctor and medical writer who 
published a best-seller in 2012 called ‘Bad Pharma – how 
Drug Companies Mislead Doctors and Harm Patients’ (the 
book was endorsed by the founder of the prestigious Co-
chrane Library in the UK).11 In this book, Big Pharma’s 
failings to protect public health benefits in the West are 
highlighted. He argues that aggressive marketing of super-
fluous or dangerous drugs, embezzlement of clinical data 
and lack of independent science and information are the 
rule instead of the exception, with regulations in Europe 
and the US being increasingly dominated and manipulated 
by the industry. The book gives examples where patient 
safety was knowingly compromised, and refers to the in-
creasing number of clinical studies that are performed in 
developing countries to escape the strict regulations and 
high costs in the West. What would an in depth investiga-
tion reveal about the behavior of Big Pharma in develop-
ing countries, where regulations are not only much less 
strict, but in many cases not enforced? The thought is 
deeply unsettling. 
In the last decade, popular fiction included some seething 
exposees on the greed and ruthlessness of Big Pharma in 
Africa, such as John Le Carre’s book ‘The Constant Gar-
dener’, made into a Hollywood movie in 2005. The author 
stated in the credits that “nobody in this story, and no outfit 
or corporation, thank God, is based upon an actual person 
or outfit in the real world, but I can tell you this, as my jour-
ney through the pharmaceutical jungle progressed, I came 
to realize that, by comparison with the reality, my story 
was as tame as a holiday postcard”. The book was based 
on a real event that took place in Kano, Nigeria. During 
a severe meningitis epidemic and in a hospital overflow-
ing with patients, Pfizer decided to test a new antibiotic, 
named Trovan. The drug was Pfizer’s most promising at 
the time with projected annual sales of over a billion US$ 
a year, but it was not yet approved in the USA. In animal 
tests it was shown that it might cause significant side ef-
fects in children such as joint disease, bone deformation 
and liver damage. Yet, the trial in Nigeria tested the drug in 
children with Pfizer cutting serious ethical corners; most 
parents of the children who were enrolled could not speak 
or read English, and did not understand that the proposed 
treatment was experimental and that a safe, approved treat-
ment was offered in the same hospital for free. After two 
weeks the trial was finished and the Pfizer team left Kano, 
to never return for follow-up evaluations. Of 200 children, 
11 died and others became paralyzed, deaf or blind (Pfizer 
later reached a settlement of 75 million US$ with the Ni-
gerian authorities). Pfizer filed for US FDA approval for 
Trovan’s use in children based on the Kano trial, but failed 
to obtain it. However, the drug was approved for adults 
and entered the US and European markets in 1998 where 
it immediately became a top-selling drug. But in 1999, less 
than a year later, it became apparent that the drug caused 
serious liver damage in adult patients. Trovan was with-
drawn from the European market and is only allowed for 
a small group of selected patients in hospitals and nursing 
homes in the USA. 
A chilling book written by the famous Swedish detec-
tive writer Henning Mankell, named ‘Kennedy’s Brain’, 
described the activities of a multinational pharmaceutical 
company in an unacknowledged clinic, set in a remote cor-
ner of Mozambique. In this clinic, HIV drugs were tested 
on infected victims without their consent, and healthy Af-
ricans were unwittingly infected with HIV and held in cap-
tivity so that the new drugs could also be tested on those 
who were recently infected. The writer, who now lives in 
Mozambique and works with charities that help people 
living with HIV, stated in his book that he could not write 
11 Bad Pharma – how Drug Companies Mislead Doctors and Harm 
Patients. Ben Goldacre, Sept 2012, ISBN: 978-0-00-735074-2
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non-fiction about what he knew of the situation in Africa 
because few would take him seriously. 
We may never know the truth of what actually happened in 
these and other remote settings. Surely the question what 
harm Pharma’s corporate greed can do in an environment 
where there is an absence of regulations is a very poignant 
one. For one, the active marketing of drugs in developing 
countries that have been disapproved for use in the West 
has been well documented.12 
Big Pharma’s aggressive marketing practices themselves 
are a subject of much debate and public outrage.11 A recent 
statement by GSK (‘Do More, Feel Better, Live Longer’), 
introducing a new sales scheme for pharmaceuticals, said 
the following:
‘Our new (compensation) programme will have no indi-
vidual sales targets. Instead, GSK’s sales professionals 
who work directly with prescribing healthcare profes-
sionals will be evaluated and rewarded for their techni-
cal knowledge, the quality of the service they deliver to 
support improved patient care and the overall performance 
of GSK’s business’. The programme bases compensation 
for sales professionals who work directly with prescribing 
healthcare professionals on a blend of qualitative measures 
and the overall performance of their business, rather than 
the number of prescriptions generated’. 13
This directly reflects current practice: as in any other in-
dustry, sale targets are paramount. This statement of GSK 
was published soon after it received a record 3 billion US$ 
fine for marketing drugs beyond their authorized uses. 
Fines of this magnitude for off-label promotion are com-
mon among Big Pharma: Pfizer (‘Working for a Healthier 
World’) was fined US$ 2.3 billion in 2010, and Abbott 
(‘A Promise for Life’) US$ 1.5 billion in 2012. In 2013 
Chinese authorities announced that in the last 5 years, the 
bribes and sexual favors that GSK had provided to man-
agers, doctors, hospitals and others who prescribed GSK 
drugs amounted to nearly 0,5 billion US$. 
Probably one of the direst consequences of an entirely 
market-driven drug industry is the lack of investment into 
drugs for diseases that predominantly affect poor people 
in poor countries and for which there is little or no market 
potential. There is no financial incentive to invest in R&D 
for these so-called neglected diseases, for which in many 
cases no safe and effective drugs exist. According to the 
World Health Organization (WHO), Sub-Saharan Africa 
has 11% of the world’s population, yet it accounts for 24% 
of the global disease burden. A study in 1999 demonstrat-
ed that of 1,393 new medicines launched globally between 
1975 and 1999, only 13 (1%) were for tropical infectious 
diseases. But as 10 of these 13 drugs were developed for 
veterinary or military purposes, only three that were the 
result of genuine efforts to create drugs for these neglected 
diseases.14 There is little indication that the situation is 
improving; just 4% of new drugs and vaccines approved 
between 2000 and 2011 were for neglected tropical dis-
eases.15 Some recent progress has been made, such as the 
r ‘London Declaration on Neglected Tropical Diseases’, a 
large scale coordinated initiative by government, industry 
and other stakeholders, launched in January 2012. It aims 
to eradicate 10 neglected diseases by 2020 and provide 
785 US$ to support R&D. This initiative was officially en-
dorsed by the 13 leading pharmaceutical companies; how-
ever, one of these, AstraZeneca (‘Life Inspiring Idea’s), re-
cently announced it was pulling out of all early stage R&D 
for malaria, tuberculosis and neglected tropical diseases. 
The company stated it will only invest in drugs for cancer, 
diabetes, and high blood pressure; the chronic diseases of 
the affluent.1 
  
A voluntary fund, to which pharmaceutical corporations 
would contribute an agreed percentage of their profits for 
R&D for neglected diseases, has been proposed as a po-
tential solution to this problem. But as yet, attempts at de-
veloping codes of conduct that rely on voluntarism have 
12 See, for example: Dipryone, a drug no one needs, BukoPharma
 http://www.en.bukopharma.de/uploads/file/Archiv/Dipyrone-
ADrugNo-oneNeeds.pdf
13 GSK announces changes to its global sales and marketing practices 
to further ensure patient interests come first. Press release GSK, Dec 
17, 2013. www.gsk.com
14 Fatal Imbalance. The Crisis in Research and Development for Drugs 
for Neglected Diseases. DNDi. 
 http://www.dndi.org/images/stories/press_kit/rnd/pdfs/fatal_
imbalance_2001.pdf
15 B Pedrique, N Strub-Wourgaft, C Some. The drug and vaccine land-
scape for neglected diseases (2000-11): a systematic assessment, 
Lancet 1, 6, 2013
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not been successful in ensuring accountability. The term 
‘corporate social responsibility’ (CSR) became popular in 
the 1960s, and is now routine in business strategy, but it 
is commonly acknowledged that it is failing to deliver for 
both companies and society. A recent report by Mc Kinsey 
outlined that ‘traditional CSR’ relies on three tools: a full-
time CSR team in the head office, some high-profile (but 
relatively cheap) initiatives, and a glossy annual review 
of progress; and that companies often see CSR as an ex-
ercise in protecting their reputation and get away with ir-
responsible behavior.16 CSR is not by any stretch adequate 
to ensure global access to drugs. As in all other industries, 
Pharma’s corporate strategy does not include a human 
rights agenda. Even the idea that businesses have obliga-
tions regarding human rights is relatively new and contro-
versial. Although corporate accountability standards, such 
as the UN Human Rights Norms for Business, have been 
endorsed by many stakeholders, they are not likely to be-
come legally enforceable. 
Recent studies have given insight in the underlying mech-
anism of corporate greed and the unprecedented levels 
of economic inequality of these times. The US Berke-
ley scientist Paul Pfiff demonstrated via multiple experi-
ments that increased wealth and status in society lead to 
increased self-focus and, in turn, decreased compassion, 
altruism, and ethical behavior.17 The experiments showed, 
for example, that those who drive expensive cars are far 
more inclined to break the law and even that people con-
sidering themselves rich will take twice as much candy 
from a jar that was specifically identified as being reserved 
for children than the less well-off. The more wealthy one 
is, the more inclined to bribe, promote unethical behav-
ior, steal and lie; the more severe inequality becomes, the 
more entitled the privileged will feel and the less likely to 
share resources. These experiments however also showed 
how small psychological interventions can fully restore 
empathy and egalitarian behavior. A direct confrontation 
with the needs of others, for example via a short video 
on child poverty, will generate compassionate behavior 
in equal measure in the rich and the poor. Indeed, as the 
world becomes more transparent through internet, twitter 
and whistleblowers, and global awareness of inequity and 
the suffering it causes is increasing, its effect becomes ap-
parent in society. Initiatives where the extremely wealthy 
dedicate a large part of their resources to charity are be-
coming more and more common. The Bill and Melinda 
Gates Foundation and the Giving Pledge, in which more 
than 100 of America’s wealthiest pledged half of their for-
tune to combat inequity, are examples of the very privi-
leged acting on the impulse of compassion. Why are big 
corporations, and specifically Big Pharma, lagging behind? 
Is the simple answer that its decision-makers are emotion-
ally disconnected from the reality on the ground that their 
company strategies create? 
BOX
WHO, 10 June 2013: “I am deeply concerned by two 
recent trends. The first relates to trade agreements. 
Governments introducing measures to protect the 
health of their citizens are being taken to court, and 
challenged in litigation. This is dangerous. The second 
is efforts by industry to shape the public health policies 
and strategies that affect their products. When indus-
try is involved in policy-making, rest assured that the 
most effective control measures will be downplayed 
or left out entirely. This, too, is well documented, and 
dangerous.”
Dr Margaret Chan
Director-General of the World Health Organization
Opening address at the 8th Global Conference on 
Health Promotion
Helsinki, Finland 
16 Beyond corporate social responsibility: Integrated external engage-
ment. John Browne and Robin Nuttall. March 2013. www.mckinsey.
com  
17 See for all publications of Dr Pfiff: paulpiff.wix.com/paulpfiff and 
for a summary of his work: http://www.ted.com/talks/paul_piff_
does_money_make_you_mean
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BOX
Big Pharma slogans 
Merck. Where patients come first.
Pfizer. Working for a healthier world.
Sanofi-Aventis. Because health matters.
GlaxoSmithKline. Do more, feel better, live longer.
Bayer. Science for a better life.
Novartis. Caring and Curing.
Astra Zeneca. Life Inspiring Idea’s. 
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